Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

Saved in:
Bibliographic Details
Title: Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.
Authors: Stintzing S; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology (CCM), Berlin, Germany. Electronic address: sebastian.stintzing@charite.de., Tabernero J; Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology, Centro Cellex, Barcelona, Spain., Satoh T; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Dasari A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Lonardi S; Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Eng C; Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, USA., Garcia-Carbonero R; Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Elez E; Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology, Centro Cellex, Barcelona, Spain., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Sobrero AF; Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy., Yao JC; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany., Arnold D; Department of Oncology and Hematology, Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany., Basic E; Department of Business and Economics, Berlin School of Economics and Law, Berlin, Germany., Granold M; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany., Petschulies M; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany., Wu L; Takeda Development Center Americas, Inc. (TDCA), Lexington, USA., Chung YC; Takeda Development Center Americas, Inc. (TDCA), Lexington, USA., Chen L; Takeda Development Center Americas, Inc. (TDCA), Lexington, USA., Yang Z; HUTCHMED International Inc., Florham Park, USA., Van Cutsem E; Gastroenterology/Digestive Oncology, University Hospitals Gasthuisberg/Leuven & KULeuven, Leuven, Belgium.
Source: ESMO open [ESMO Open] 2025 Mar; Vol. 10 (3), pp. 104297. Date of Electronic Publication: 2025 Feb 21.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-7029
DOI:10.1016/j.esmoop.2025.104297